Member Info for inanaco

you have failed to assign any growth to the IP from that funding

it's pointless having a one sided debate .. when Scancell has not RNS for a EGM on funding

if you can't cope with the heat Tommy and your troubled ......... exit

fully funded to phase 2 ... non dilutive

£5m sale of Antibodies ...

Ray

They cannot delay .... if they do, they lose the option

far better to IPO with a business plan associated with Moditope as you raise the funding for that program

just to remind you

As expected, and in line with the Company’s commercialisation plans, an option fee will be payable (within 30
days of exercise) to Ichor, with further milestone payments due from the start of future Phase 3 clinical trials.
The Company has also granted an extension of the period for exercise of the Tranche 2 share options
(3,184,620 ordinary shares) issued as part payment for the licence option, which will be immediately exercised
by, subscribed for and allotted to Ichor, as part of the Company’s exercise of the commercial licence option.
Ichor has agreed to hold these Tranche 2 shares for a period of at least two years from their date of issue

i have emailed the MP in question (griffiths) .. with a full update of scancell, asking him to get behind the research and trials etc.

Immunotherapy just been highlighted in the House

Have signed up to an exclusive option

""" BioNTech will have the exclusive option to enter into a licence agreement """

these option agreements are time limited ...

i suggest you do some more research before you compare them to NDA (non disclosure agreement)

that's why he added the word "forensic" ... makes it sound more Bio ....

LOL

Out comes the VAL regulars in support of there front man ..Knowlesi ...

Love it

missed of and before who

As lindy has already highlighted, TCR with NON SIPTM neo-antigens work, but not in the patient numbers as yet to justify the enormous cost of delivery ... which is why great efforts with Siemens to streamline the complexity of manufacture

Now you cannot say that this plan is not commercial ... as Biontech and now Roche have expanded TCR or in Roche case bought a TCR platform ...

Now Personal Neo Antigens are rarely transferable between patients .. so you end up building an epitope "pool" not in 10' but potentially 100.000 's with all the storage and infrastructure of support of that quantity of Viral vectors containing the TCR and you still have to test every patients sample to identify

Moditope is sheer genius ... because the Neo antigens epitopes are universal across 17 cancers and 90% odd of patients ...

The fact that the collaboration has gone on for so long indicates that the outcome will indeed be positive reinforced with the Staff Hires .

so you have to look at the existing TCR technology of building 100,000 vectors

or

Moditope ............ building 3 ..... with the back up of Homocitrulline Combo's

Then try and place value on that considering you now have Big Pharma bringing TCR to the mainstream

the reason why its so important is the toxicity compared with Car T .... and the ability to attack late stage tumour bypassing the NEED for PD-1 ....

so all you have to look at is the VALUE of the PD-1 market and the way it's grown to see that Moditope has an even bigger potential ...

Just one trial will prove it up ...........

DUP no support

it's a game of poker ..........

always has been

nothing wrong with reprinting the editorial ..

C7

I have just proved he is buying to average Down .......... or he sold at a big loss and is trying to recover that position with more shares for his buck ...

get the sp down .......... create negative sentiment ... buy cheap

knowlesi - 29 Mar 2017 - 13:07:03 - 8955 of 20507 Using immunology to fight cancer. - SCLP
Lozan - once we have funding - and three trials on the go 1) scib1 combo, 2) scib2 combo 3) modi 1 trial - given these will all target late stage very ill patients - it will become clear early on whether we are having success - in the case of the combo trials - whether they are extending life beyond the pd1 control arm. In the case of modi1 if it can do in humans what it's doing in animal models. If any of those hit - we'll see £6 and then some. If they all hit - way way beyond £6. The 18 month timeline isn't beyond the realms of possibility. I think you are possibly playing the man and not the ball here - please be better than them and consider the argument on its merits. An obnoxious oaf he may be but it's not beyond the realms of possibility. Where I disagree is the path to get there - we haven't seen the bottom yet and it won't be a straight line imo. Let's see - further weakness to come but sp £6 in 18 months - yeah potentially if the trials prove outstanding. Let's just hope we smash the control arm data and there is a clear merit shown in trials to the combo - both safety and efficiency - the science seems certain but until we see it in trials it won't be valued as such...

posted the full text ..... not hand picked

indeed ... bits include your delusional .. C7 is GF123

you have not got SCLP correct ....................

But in your heart and mind you know what will happen if i have it correct !!! £6 ... lol after all you agreed with me

well somebody Paid City F. .......... so why worry ! have you thought about an open buy order ? no sure if MM can do that .... maybe somebody has left an offer in for all the share ... sitting ... waiting